Form 4: Shattuck Labs Director Reports OrbiMed Warrant Acquisition

Director Mona Ashiya reports the acquisition of pre-funded warrants by OrbiMed-affiliated entities following a public offering.

Summary

• Director Mona Ashiya filed a Form 4 disclosing the acquisition of pre-funded warrants by OrbiMed Private Investments IX, LP and OrbiMed Genesis Master Fund, L.P.
• The acquisition follows a public offering by Shattuck Labs, Inc. that closed on June 11, 2026.
• OrbiMed Private Investments IX, LP acquired 1,041,667 pre-funded warrants.
• OrbiMed Genesis Master Fund, L.P. acquired 208,333 pre-funded warrants.
• The warrants have an exercise price of $0.0001 per share and are exercisable immediately, subject to a 9.99% beneficial ownership blocker.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive event; while it confirms institutional support and successful capital raising, it also highlights the dilutive nature of the recent financing.

Positives

• Successful completion of a public offering indicates continued capital access for the company.
• Significant participation by existing major institutional investors (OrbiMed) signals confidence in the company's long-term prospects.

Negatives

• The issuance of additional shares and warrants results in dilution for existing shareholders.

Risks

• The 9.99% beneficial ownership blocker on the warrants limits the immediate conversion capacity for the reporting entities.
• Market volatility associated with public offerings and potential future dilution.

Future Outlook

The filing does not provide specific forward-looking guidance, but notes that the pre-funded warrants are exercisable at any time after issuance.

Industry Context

StockSavvy.ai notes that this transaction is consistent with typical capital-raising activities for clinical-stage biotechnology companies, where institutional investors often utilize pre-funded warrants to maintain ownership stakes while navigating regulatory ownership thresholds.

Comparison to Industry Standards

• The use of pre-funded warrants is a standard mechanism in biotech equity offerings to avoid immediate ownership concentration above regulatory limits.
• The pricing structure aligns with standard market practices for follow-on offerings in the life sciences sector.

Related Party Transactions

• The reporting person is affiliated with OrbiMed, which holds significant equity in the issuer.

Stakeholder Impact

• Existing shareholders face dilution due to the issuance of new shares and warrants.
• Institutional investors maintain their relative influence through the acquisition of warrants.

Next Steps

• Potential future exercise of the pre-funded warrants by OrbiMed entities.

Key Dates

Recommendation

The filing reflects a standard capital raise. While institutional backing is a positive signal, the dilution inherent in the offering suggests a hold position until further clinical or operational milestones are achieved.

Keywords

Shattuck Labs, STTK, OrbiMed, Form 4, Pre-funded warrants, Insider transaction, Biotech